News

Net loss for the year ended December 31, 2008 was $8.5 million, or $0.16 per diluted share, compared to a net loss of $18.3 million, or $0.35 per

The product will be marketed under store brand labels and is comparable to Wyeth Consumer Healthcare’s Advil PM tablets, 200/38mg, indicated as a pain reliever non-steroidal anti-inflammatory drug/nighttime

Investors also received 0.75 of a warrant, exercisable at a price of $2.15 per share, for each share of common stock. The warrants have a three-year term from

Richard Garr, president and CEO of Neuralstem, said: “The FDA has presented us with their review of our entire investigational new drug application. They have asked for some

According to Revolutions Medical, the Rev Vac safety syringe uses patented technology to draw the needle back into the syringe chamber after use. This safety syringe is expected

The Phase I study will assess the safety, pharmacokinetics and anti-tumor activity of NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available

The company is developing LX214 as a potential treatment for keratoconjunctivitis sicca, commonly known as dry eye syndrome, and other chronic inflammatory ocular surface diseases. Lux has filed

Cubist said that this Phase I trial is the first time CB-182,804 has been given to humans and is designed to evaluate the safety and pharmacokinetics of CB-182,804

While the product meets all the FDA’s requirements for manufacturing quality, clinical safety and efficacy, the company must resolve certain patent issues related to the reference product, Ultram